Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study

Mark A. Crowther, David Garcia, Walter Ageno, Luqi Wang, Dan M. Witt, Nathan P. Clark, Mark D. Blostein, Susan R. Kahn, Sam Schulman, Michael Kovacs, Marc A. Rodger, Philip Wells, David Anderson, Jeffrey Ginsberg, Rita Selby, Sergio Siragusa, Mauro Silingardi, Mary Beth B. Dowd, Clive Kearon

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Unanticipated elevation of the INR is common in patients receiving warfarin. We performed a prospective cohort study of 107 warfarintreated patients with INR values of more than 10 who received a single 2.5 mg dose of oral vitamin K. During the first week, one patient experienced major bleeding, and one died. In the first 90 days after enrolment four patients had major bleeding (3.7%, 1.0% to 9.3%), eight patients (7.5%, 3.3% to 14.2%) died and two had objectively confirmed thromboembolism. Based on our low rate of observed major bleeding we conclude that 2.5 mg of oral vitamin K is a reasonable treatment for patients with INR values of more than 10 who are not actively bleeding.

Original languageEnglish
Pages (from-to)118-121
Number of pages4
JournalThrombosis and Haemostasis
Volume104
Issue number1
DOIs
StatePublished - Jul 2010
Externally publishedYes

Keywords

  • Acquired coagulation disorders
  • Haemostasis
  • Oral anticoagulants
  • Thrombosis

Fingerprint

Dive into the research topics of 'Oral vitamin K effectively treats international normalised ratio (INR) values in excess of 10: Results of a prospective cohort study'. Together they form a unique fingerprint.

Cite this